Results of CHOP-Bleo / CMED Alternating Chemotherapy for Aggressive Non - Hodgkin's Lymphoma.
- Author:
Suk Jin KIM
;
In Keun CHOI
;
Sang Chul OH
;
Jae Hong SEO
;
Byung Soo KIM
;
Sang Won SHIN
;
Yeul Hong KIM
;
Jun Suk KIM
- Publication Type:Original Article
- Keywords:
Cyclophosphamide-adriamycin-vincristine-prednisone-bleomycin(CHO- Bleo);
Cyclophosphamide-methotrexate-etoposide-dexamethasone(CMED);
Altemating chemotherapy;
Aggressive non-Hodgkin's lymphoma
- MeSH:
Cyclophosphamide;
Disease-Free Survival;
Drug Therapy*;
Etoposide;
Hodgkin Disease*;
Humans;
Incidence;
Leukopenia;
Lymphoma, Non-Hodgkin;
Methotrexate;
Survival Rate
- From:Journal of the Korean Cancer Association
1998;30(2):350-356
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To assess the efficacy and toxicity of a new protocol that consists of CHOP- Bleo alternated with a new regimen of Cyclophosphamide, methotrexate, etoposide, and dexamethasone(CMED) for aggressive Non-Hodgkin's Lymphoma(NHL). PATIENTS AND METHODS: Between January 1991 and December 1996, forty-six patients with Ann Arbor stages II-IV aggressive NHL were treated with alternating cycles of CHOP-Bleo and CMED for a total of 12 cycles. All eligible patients were evaluated for response, disease-free survival, and overall survival. RESULTS: Twenty-two patients(47.8%) achieved a complete response and overall response rate was 83.9%. The range of survival duration was 1-68+months and the median survival time was 42 months. Overall 3-year survival rate was 54%. The range of disease-free survival time was 6-63+months and 3-year disease-free survival rate was 61%. The most common hematologic toxicity was leukopenia and the incidence of severe leukopenia(<1,000/mm3) was 11%. And alopecia(84.8%) was the most common non-hematologic toxicity. CONCLUSION: The results of CHOP-Bleo/CMED alternating chemotherapy for patients with aggressive Non-Hodgkin's Lymphoma is not superior to other results of previous studies. Therefore further study will be warranted to determine clinical effectiveness of alternating chemotherapy.
